论文部分内容阅读
目的 :观察胆维他与普伐他汀联合治疗难治性原发性高脂血症的临床疗效及不良反应。方法 :对 80例经规则服辛伐他汀或普伐他汀或非诺贝特治疗 12周无效的难治性原发性高脂血症病人按数字随机法分胆维他与普伐他汀联合治疗组及继续按原方案治疗组 (对照组 )。比较两组治疗前后血脂水平变化和两组间的疗效及不良反应。结果 :联合治疗组治疗后的总胆固醇、甘油三酯、低密度脂蛋白分别下降 2 4.3%、 2 1.1%和 2 6 .5 %。前后对比均有非常显著性差异 (P <0 .0 1)。对照组分别下降 1.6 %、 2 .3%和 3.1% ,前后对比均无显著性差异 (P >0 .0 5 ) ,两组高密度脂蛋白升高分别为 8.2 %和 6 .5 %均无显著性差异 (P >0 .0 5 )。两组疗效对比联合治疗组显著优于对照组 (P <0 .0 1) ,联合治疗组的不良反应明显少于对照组(P <0 .0 5 )。结论 :胆维他与普伐他汀联合治疗难治性原发性高脂血症效果好 ,副作用少
Objective: To observe the clinical efficacy and adverse reactions of b-Vita combined with pravastatin in the treatment of refractory primary hyperlipidemia. Methods: Eighty patients with refractory idiopathic hyperlipidemia who were treated with regular simvastatin or pravastatin or fenofibrate for 12 weeks were divided into two groups according to the randomized treatment with bilepide combined with pravastatin Group and continue the original program treatment group (control group). Blood lipid levels before and after treatment were compared between the two groups and the efficacy and adverse reactions between the two groups were compared. Results: After treatment, total cholesterol, triglyceride and low density lipoprotein decreased by 23.3%, 21.1% and 26.5% respectively in the combined treatment group. Before and after the contrast has a very significant difference (P <0. 01). The control group decreased by 1.6%, 2.3% and 3.1% respectively, with no significant difference between before and after treatment (P> 0.05), the HDL of the two groups were 8.2% and 6.5% respectively Significant difference (P> 0.05). The two groups were significantly better than the control group (P <0.01). The adverse reactions in the combination group were significantly less than those in the control group (P <0.05). Conclusion: The combined treatment of bovine and pravastatin is effective in treating refractory primary hyperlipidemia with few side effects